Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma

Mark Roschewski, MD, Kieron Dunleavy, MD, Sattva S. Neelapu, MD, Stefania Pittaluga, MD PhD, Christopher Joseph Melani, MD, Elaine S. Jaffe, MD, Margaret Shovlin, RN, Beryl Crossley, BS, Katie Kong, BS, Allison Jacob, MD, Larry Kwak, Wyndham H. Wilson, MD PhD

Blood (2016) 128 (22): 2943.

https://doi.org/10.1182/blood.V128.22.2943.2943

Published: 2016

Journal Articles

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Bertrand Coiffier, Juan-Manuel Sancho, Wojciech Jurczak, Jin Seok Kim, Raj V Nagarkar, Edvard Zhavrid, Jose Angel Hernandez Rivas, Aliaksandr Prokharau, Mamia Zodelava, Dzhelil Osmanov, Michinori Ogura, Christian Buske, Larry Kwak, Sang Joon Lee, Sung Young Lee, Yun Ju Bae, Won Seog Kim

Blood (2016) 128 (22): 1807.

https://doi.org/10.1182/blood.V128.22.1807.1807

Published: 2016

Journal Articles

Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation

Blood (2016) 128 (22): 4548.

https://doi.org/10.1182/blood.V128.22.4548.4548

Published: 2016

Journal Articles

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

Zheng Chen, Robert Z. Orlowski, Michael Wang, Larry Kwak, Nami McCarty

Blood (2014) 123 (14): 2204–2208.

https://doi.org/10.1182/blood-2013-07-517136

Published: 2014

Includes: Supplemental data

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Michelle A. Fanale, MD, Chao-Ming Lai, APN, Peter McLaughlin, MD, Jorge Romaguera, MD, Luis Fayad, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, MPH, Maria Alma Rodriguez, MD, Sattva S. Neelapu, Jatin J Shah, MD, Larry Kwak, Wenli Dong, Valerie Reed, MD, Bouthaina S. Dabaja, MD, Uday Popat, MD, Anas Younes, MD

Blood (2010) 116 (21): 2812.

https://doi.org/10.1182/blood.V116.21.2812.2812

Published: 2010

Journal Articles

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Liang Zhang, MD, PhD, Jing Yang, PhD, Jianfei Qian, PhD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Michael Wang, MD, Qing Yi, MD, PhD

Blood (2010) 116 (21): 3929.

https://doi.org/10.1182/blood.V116.21.3929.3929

Published: 2010

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Non-Stereotypic Follicular Lymphoma B-Cell Receptors Recognize Vimentin as a Shared Autoantigen

Soung-Chul Cha, Hong Qin, Shivichakravarthy Kannan, Seema Rawal, PhD, Weiguo Wu, Juliana Ong, Jinsong Wei, Benjamin Kwak, Sang Kim, Michael Popescu, Daniel Paick, Richard Davis, Larry Kwak, Sattva S. Neelapu

Blood (2010) 116 (21): 139.

https://doi.org/10.1182/blood.V116.21.139.139

Published: 2010

Journal Articles

Novel PI3K Inhibitor Compound A Induces Myeloma Cell Apoptosis and Shows Synergistic Cytotoxicity with Dexamethasone In Multiple Myeloma

Yuhuan Zheng, PhD, Jing Yang, PhD, Liang Zhang, MD, PhD, Jianfei Qian, PhD, Jairo Matthews, Michael Wang, MD., Larry Kwak, Qing Yi, MD, PhD

Blood (2010) 116 (21): 4080.

https://doi.org/10.1182/blood.V116.21.4080.4080

Published: 2010

Journal Articles

Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration In Follicular Lymphoma Patients

Stephen J. Schuster, Carlos F. Santos, Sattva S. Neelapu, Donald A. Berry, Mihaela A. Popa, Amy M. McCord, Elise A. Chong, Larry Kwak

Blood (2010) 116 (21): 429.

https://doi.org/10.1182/blood.V116.21.429.429

Published: 2010

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.

Blood (2009) 114 (22): 1714.

https://doi.org/10.1182/blood.V114.22.1714.1714

Published: 2009

Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD

Blood (2009) 114 (22): 3922.

https://doi.org/10.1182/blood.V114.22.3922.3922

Published: 2009

Journal Articles

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, MD, Leo Gordon, MD, Stella Kim, MD, Jorge Romaguera, MD, Amanda R Copeland, MS, Silvana de Castro Farial, MD, Larry Kwak, MD, PHD, Luis Fayad, MD, Frederick Hagemeister, MD, Michelle Fanale, M.D., John Lambert, PhD, Teresa Bagulho, MD, Rodica Morariu-Zamfir, MD

Blood (2009) 114 (22): 585.

https://doi.org/10.1182/blood.V114.22.585.585

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD, Luis Fayad, Peter McLaughlin, MD, Barbara Pro, MD, Maria Alma Rodriguez, MD, Michael Wang, MD, Pamela Weaver, RN, Kimberly Hartig, Larry Kwak, MD, PhD, Tatyana Feldman, MD, Judy Smith, RN, Peggy Ford, RN, Stuart Goldberg, MD, Andrew Pecora, MD, Andre Goy, MD

Blood (2008) 112 (11): 3051.

https://doi.org/10.1182/blood.V112.11.3051.3051

Published: 2008

Journal Articles

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Jorge Romaguera, Luis Fayad, Alma Rodriguez, Fb Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Jatin Shah, Pamela Weaver, Kim Hartig, Fernando Cabanillas, Larry Kwak, Hagop Kantarjian, Michael Wang

Blood (2008) 112 (11): 833.

https://doi.org/10.1182/blood.V112.11.833.833

Published: 2008

Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD

Blood (2007) 110 (11): 2562.

https://doi.org/10.1182/blood.V110.11.2562.2562

Published: 2007

NARROW

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Non-Stereotypic Follicular Lymphoma B-Cell Receptors Recognize Vimentin as a Shared Autoantigen

Novel PI3K Inhibitor Compound A Induces Myeloma Cell Apoptosis and Shows Synergistic Cytotoxicity with Dexamethasone In Multiple Myeloma

Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration In Follicular Lymphoma Patients

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only